gamma-aminobutyric acid has been researched along with Delirium of Mixed Origin in 23 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although postoperative opioid use was reduced, perioperative administration of gabapentin did not result in a reduction of postoperative delirium or hospital length of stay." | 9.24 | Perioperative Gabapentin Does Not Reduce Postoperative Delirium in Older Surgical Patients: A Randomized Clinical Trial. ( Ames, C; Berven, S; Bozic, K; Burch, S; Chang, S; Chen, N; Chou, D; Covinsky, K; Deviren, V; Kinjo, S; Kramer, JH; Leung, JM; Meckler, G; Newman, S; Ries, M; Sands, LP; Tay, B; Tsai, T; Vail, T; Voss, V; Weinstein, P; Youngblom, E, 2017) |
| "In this randomized pilot clinical trial, the authors tested the hypothesis that using gabapentin as an add-on agent in the treatment of postoperative pain reduces the occurrence of postoperative delirium." | 9.12 | Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients. ( Ames, C; Chou, D; Dahl, JB; Leung, JM; Petersen, KL; Rico, M; Rowbotham, MC; Sands, LP; Weinstein, P, 2006) |
| "Gabapentin (Neurontin) is approved by the US Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia." | 7.75 | Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009) |
| "Gabapentin was shown to be opioid sparing, with lower doses for the intervention group versus the control group." | 6.84 | Perioperative Gabapentin Does Not Reduce Postoperative Delirium in Older Surgical Patients: A Randomized Clinical Trial. ( Ames, C; Berven, S; Bozic, K; Burch, S; Chang, S; Chen, N; Chou, D; Covinsky, K; Deviren, V; Kinjo, S; Kramer, JH; Leung, JM; Meckler, G; Newman, S; Ries, M; Sands, LP; Tay, B; Tsai, T; Vail, T; Voss, V; Weinstein, P; Youngblom, E, 2017) |
| "Delirium is a common complication in postoperative, critically ill patients." | 5.40 | The association of plasma gamma-aminobutyric acid concentration with postoperative delirium in critically ill patients. ( Egi, M; Kanazawa, T; Morita, K; Toda, Y; Yoshitaka, S, 2014) |
| "Gabapentin is a central nervous system inhibitory agent with likely gamma-aminobutyric acid (GABA)-ergic and non-GABAergic mechanisms of action." | 5.35 | Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009) |
| "Although postoperative opioid use was reduced, perioperative administration of gabapentin did not result in a reduction of postoperative delirium or hospital length of stay." | 5.24 | Perioperative Gabapentin Does Not Reduce Postoperative Delirium in Older Surgical Patients: A Randomized Clinical Trial. ( Ames, C; Berven, S; Bozic, K; Burch, S; Chang, S; Chen, N; Chou, D; Covinsky, K; Deviren, V; Kinjo, S; Kramer, JH; Leung, JM; Meckler, G; Newman, S; Ries, M; Sands, LP; Tay, B; Tsai, T; Vail, T; Voss, V; Weinstein, P; Youngblom, E, 2017) |
| "In this randomized pilot clinical trial, the authors tested the hypothesis that using gabapentin as an add-on agent in the treatment of postoperative pain reduces the occurrence of postoperative delirium." | 5.12 | Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients. ( Ames, C; Chou, D; Dahl, JB; Leung, JM; Petersen, KL; Rico, M; Rowbotham, MC; Sands, LP; Weinstein, P, 2006) |
| "Gabapentin (Neurontin) is approved by the US Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia." | 3.75 | Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009) |
| "Gabapentin was shown to be opioid sparing, with lower doses for the intervention group versus the control group." | 2.84 | Perioperative Gabapentin Does Not Reduce Postoperative Delirium in Older Surgical Patients: A Randomized Clinical Trial. ( Ames, C; Berven, S; Bozic, K; Burch, S; Chang, S; Chen, N; Chou, D; Covinsky, K; Deviren, V; Kinjo, S; Kramer, JH; Leung, JM; Meckler, G; Newman, S; Ries, M; Sands, LP; Tay, B; Tsai, T; Vail, T; Voss, V; Weinstein, P; Youngblom, E, 2017) |
| "Delirium is a very common and serious disorder with high morbidity and mortality." | 2.45 | Pharmacological treatment for the prevention of delirium: review of current evidence. ( Howard, R; Tabet, N, 2009) |
| "However, delirium is underrecognized and undertreated because of its heterogeneous and fluctuating presentation and due to the limitations in resources and training in contemporary clinical settings." | 2.44 | Delirium: where do we stand? ( Han, C; Marks, DM; Masand, P; Pae, CU; Patkar, AA, 2008) |
| "Gabapentin is a second generation anticonvulsant that is effective in the treatment of chronic neuropathic pain." | 2.44 | Gabapentin: a multimodal perioperative drug? ( Irwin, MG; Kong, VK, 2007) |
| "Infant delirium is an under-recognized clinical entity in neonatal intensive care, and earlier identification and treatment could minimize morbidities associated with this condition." | 1.46 | A case of infant delirium in the neonatal intensive care unit. ( Bidegain, M; Cotten, CM; Edwards, LE; Hornik, CD; Hutchison, LB; Smith, PB, 2017) |
| "Delirium is a common complication in postoperative, critically ill patients." | 1.40 | The association of plasma gamma-aminobutyric acid concentration with postoperative delirium in critically ill patients. ( Egi, M; Kanazawa, T; Morita, K; Toda, Y; Yoshitaka, S, 2014) |
| "Delirium is still one of the most common and distressing symptoms in palliative care patients." | 1.38 | Reversible delirium in an advanced cancer patient. ( Jagsch, C; Kierner, KA; Watzke, HH, 2012) |
| "Gabapentin is a central nervous system inhibitory agent with likely gamma-aminobutyric acid (GABA)-ergic and non-GABAergic mechanisms of action." | 1.35 | Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009) |
| "Delirium is thought to be a temporary psychiatric disorder resulting from a reduced central cholinergic transmission, combined with an increased dopaminergic transmission." | 1.33 | Psychotogenic drugs and delirium pathogenesis: the central role of the thalamus. ( Gagnon, P; Gaudreau, JD, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (34.78) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Cooper, JJ | 1 |
| Ross, DA | 1 |
| Joshi, YB | 1 |
| Friend, SF | 1 |
| Jimenez, B | 1 |
| Steiger, LR | 1 |
| Leung, JM | 2 |
| Sands, LP | 2 |
| Chen, N | 1 |
| Ames, C | 2 |
| Berven, S | 1 |
| Bozic, K | 1 |
| Burch, S | 1 |
| Chou, D | 2 |
| Covinsky, K | 1 |
| Deviren, V | 1 |
| Kinjo, S | 1 |
| Kramer, JH | 1 |
| Ries, M | 1 |
| Tay, B | 1 |
| Vail, T | 1 |
| Weinstein, P | 2 |
| Chang, S | 1 |
| Meckler, G | 1 |
| Newman, S | 1 |
| Tsai, T | 1 |
| Voss, V | 1 |
| Youngblom, E | 1 |
| Regan, DW | 1 |
| Kashiwagi, D | 1 |
| Dougan, B | 1 |
| Sundsted, K | 1 |
| Mauck, K | 1 |
| Di Fabio, R | 1 |
| D'Agostino, C | 1 |
| Baldi, G | 1 |
| Pierelli, F | 1 |
| Salman, AE | 1 |
| Camkıran, A | 1 |
| Oğuz, S | 1 |
| Dönmez, A | 1 |
| Dighe, K | 1 |
| Clarke, H | 1 |
| McCartney, CJ | 1 |
| Wong, CL | 1 |
| Yoshitaka, S | 1 |
| Egi, M | 1 |
| Kanazawa, T | 1 |
| Toda, Y | 1 |
| Morita, K | 1 |
| Downes, MA | 1 |
| Berling, IL | 1 |
| Mostafa, A | 1 |
| Grice, J | 1 |
| Roberts, MS | 1 |
| Isbister, GK | 1 |
| Lee, YI | 1 |
| Chen, L | 1 |
| Smith, RL | 1 |
| Edwards, LE | 1 |
| Hutchison, LB | 1 |
| Hornik, CD | 1 |
| Smith, PB | 1 |
| Cotten, CM | 1 |
| Bidegain, M | 1 |
| Pae, CU | 1 |
| Marks, DM | 1 |
| Han, C | 1 |
| Patkar, AA | 1 |
| Masand, P | 1 |
| Tabet, N | 1 |
| Howard, R | 1 |
| Kruszewski, SP | 1 |
| Paczynski, RP | 1 |
| Kahn, DA | 1 |
| Kierner, KA | 1 |
| Jagsch, C | 1 |
| Watzke, HH | 1 |
| Pedroso, JL | 1 |
| Nakama, GY | 1 |
| Carneiro Filho, M | 1 |
| Barsottini, OG | 1 |
| MORRONI, OB | 1 |
| Kaneko, Y | 1 |
| Yanagihara, K | 1 |
| Kohno, S | 1 |
| Gaudreau, JD | 1 |
| Gagnon, P | 1 |
| Rico, M | 1 |
| Petersen, KL | 1 |
| Rowbotham, MC | 1 |
| Dahl, JB | 1 |
| Bhat, R | 1 |
| Rockwood, K | 1 |
| Kong, VK | 1 |
| Irwin, MG | 1 |
| Cowen, PJ | 1 |
| Nutt, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain in Surgical Patients[NCT00221338] | Phase 3 | 750 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study Prior to a Larger Randomized Controlled Trial[NCT02200172] | Phase 2 | 60 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Trial to Assess the Safety and Efficacy of the Perioperative Administration of Pregabalin in Reducing the Incidence of Postoperative Delirium and Improving Acute Postoperative Pain Management[NCT00819988] | Phase 3 | 240 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Usefulness of Bright Light Therapy in the Prevention of Delirium in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT)[NCT01700816] | 40 participants (Actual) | Interventional | 2012-10-31 | Terminated (stopped due to Low incidence of delirium.) | |||
| The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair[NCT02419443] | Phase 4 | 100 participants (Anticipated) | Interventional | 2011-08-31 | Active, not recruiting | ||
| Effect of Preoperative Pregabalin on Propofol Induction Dose[NCT01158859] | Phase 4 | 50 participants (Anticipated) | Interventional | 2010-04-30 | Completed | ||
| The Effect of Gabapentin on Acute Pain and PONV in Bariatric Surgical Patients[NCT00886236] | 62 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00221338)
Timeframe: Typically within the first week after surgery
| Intervention | days (Mean) |
|---|---|
| Gabapentin | 4.4 |
| Placebo | 4.1 |
Number of subjects who developed postoperative delirium, as measured by the Confusion Assessment Method, a validated tool for assessing delirium based on DSM-III-R, on any of the first three postoperative days. (NCT00221338)
Timeframe: postoperative days 1, 2 and 3
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 84 |
| Placebo | 72 |
Postoperative intravenous opioid doses converted to morphine equivalents. Median derived from total opioid doses on first, second and third postoperative days. (NCT00221338)
Timeframe: Study follow up period: postoperative days 1, 2 and 3
| Intervention | morphine equivalents, mg (Median) |
|---|---|
| Gabapentin | 6.7 |
| Placebo | 6.7 |
Postoperative pain as measured by Visual Analog Pain scale (0=no pain, 10=worst pain imaginable). (NCT00221338)
Timeframe: Postoperative day 1
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | 4 |
| Placebo | 4 |
Postoperative pain as measured by Visual Analog Pain scale (0=no pain, 10=worst pain imaginable). (NCT00221338)
Timeframe: Postoperative day 2
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | 3 |
| Placebo | 4 |
Postoperative pain as measured by Visual Analog Pain scale (0=no pain, 10=worst pain imaginable). (NCT00221338)
Timeframe: Postoperative day 3
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | 3 |
| Placebo | 3 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | volume percentage (vol%) of red blood ce (Median) |
|---|---|
| Bright Light Therapy | 28.20 |
| Sham Light | 26.70 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | g/dl (Median) |
|---|---|
| Bright Light Therapy | 9.70 |
| Sham Light | 9.55 |
(NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | days (Median) |
|---|---|
| Bright Light Therapy | 18 |
| Sham Light | 18.5 |
Monday, Wednesday, and Friday assessments will begin after beginning light therapy and include the Delirium Rating Scale-Revised-98 (DRS-98)and Memorial Delirium Assessment Scale (MDAS) (NCT01700816)
Timeframe: From hospital admission until the date of first documented delirium, assessed up to 28 days post-transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| Bright Light Therapy | 1 |
| Sham Light | 0 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | thousand cells/uL (Median) |
|---|---|
| Bright Light Therapy | 39 |
| Sham Light | 33.5 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | M/uL (Median) |
|---|---|
| Bright Light Therapy | 3.21 |
| Sham Light | 2.93 |
"Monday, Wednesday, and Friday assessments of the Memorial Delirium Assessment Scale (MDAS); Patients will receive assessments after beginning light therapy until day 28 post-transplant or discharge, whichever comes first.~10 item scale Items are rated on a four-point scale from 0 (none) to 3 (severe) depending on the level of impairment, rendering a maximum possible score of 30.~A score of 13 has been recommended as a cut-off for establishing the diagnosis of delirium" (NCT01700816)
Timeframe: From first documented episode of delirium until discharge from the hospital, assessed up to 28 days post-transplant
| Intervention | units on a scale (Number) |
|---|---|
| Bright Light Therapy | 18 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | K/uL (Median) |
|---|---|
| Bright Light Therapy | 2.30 |
| Sham Light | 4.75 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | mg/dl (Median) | |
|---|---|---|
| Serum Creatinine | Blood Urea Nitrogen (BUN) | |
| Bright Light Therapy | 0.66 | 9 |
| Sham Light | 0.75 | 8.5 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT (Hematopoietic Stem Cell Transplantation). (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | mmol/L (Median) | |||
|---|---|---|---|---|
| Sodium (Na) | Potassium (K) | Chloride (Cl) | Carbon Dioxide (CO2) | |
| Bright Light Therapy | 139 | 3.6 | 105 | 24.9 |
| Sham Light | 138.0 | 3.80 | 103.0 | 25.10 |
(NCT00886236)
Timeframe: 48 hours
| Intervention | % oxygen saturation (Mean) |
|---|---|
| 1 Preoperative Gabapentin Liquid | 93 |
| 2 Preoperative and Postoperative Gabapentin Liquid | 94 |
| 3 Preoperative and Postoperative Placebo Liquid | 95 |
The amount of intraoperative and postoperative opioids used will be collected and analyzed for the three different arms. (NCT00886236)
Timeframe: 120 hours
| Intervention | ml (Mean) |
|---|---|
| 1 Preoperative Gabapentin Liquid | 11.035 |
| 2 Preoperative and Postoperative Gabapentin Liquid | 8.7 |
| 3 Preoperative and Postoperative Placebo Liquid | 12.4 |
(NCT00886236)
Timeframe: 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Preoperative Gabapentin Liquid | 12 |
| 2 Preoperative and Postoperative Gabapentin Liquid | 11 |
| 3 Preoperative and Postoperative Placebo Liquid | 12 |
5 reviews available for gamma-aminobutyric acid and Delirium of Mixed Origin
| Article | Year |
|---|---|
Update in perioperative medicine: practice changing evidence published in 2016.
Topics: Amines; Analgesics; Anticoagulants; Antipsychotic Agents; Arthritis, Rheumatoid; Blood Transfusion; | 2017 |
Delirium: where do we stand?
Topics: Delirium; Diagnostic and Statistical Manual of Mental Disorders; gamma-Aminobutyric Acid; Humans; Ri | 2008 |
Pharmacological treatment for the prevention of delirium: review of current evidence.
Topics: Amines; Anti-Inflammatory Agents; Anticonvulsants; Antipsychotic Agents; Central Nervous System Depr | 2009 |
[Delirium induced by antimicrobial agents].
Topics: Animals; Anti-Infective Agents; Binding, Competitive; Delirium; Diagnosis, Differential; Dose-Respon | 2004 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
4 trials available for gamma-aminobutyric acid and Delirium of Mixed Origin
| Article | Year |
|---|---|
Perioperative Gabapentin Does Not Reduce Postoperative Delirium in Older Surgical Patients: A Randomized Clinical Trial.
Topics: Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Delirium; Double-Blind Me | 2017 |
Gabapentin premedication for postoperative analgesia and emergence agitation after sevoflurane anesthesia in pediatric patients.
Topics: Amines; Anesthesia, General; Anesthetics, Inhalation; Anti-Anxiety Agents; Child; Child, Preschool; | 2013 |
Perioperative gabapentin and delirium following total knee arthroplasty: a post-hoc analysis of a double-blind randomized placebo-controlled trial.
Topics: Aged; Amines; Analgesics; Arthroplasty, Replacement, Knee; Cyclohexanecarboxylic Acids; Delirium; Do | 2014 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
14 other studies available for gamma-aminobutyric acid and Delirium of Mixed Origin
| Article | Year |
|---|---|
COVID-19 Catatonia-Would We Even Know?
Topics: Akinetic Mutism; Basal Ganglia; Benzodiazepines; Betacoronavirus; Catatonia; Coronavirus Infections; | 2020 |
Dissociative Intoxication and Prolonged Withdrawal Associated With Phenibut: A Case Report.
Topics: Adult; Baclofen; Delirium; GABA Agonists; gamma-Aminobutyric Acid; Humans; Male; Substance Withdrawa | 2017 |
Delirium after gabapentin withdrawal. Case report.
Topics: Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Delirium; Electroencephalography; Epilep | 2013 |
The association of plasma gamma-aminobutyric acid concentration with postoperative delirium in critically ill patients.
Topics: Critical Illness; Delirium; gamma-Aminobutyric Acid; Humans; Multivariate Analysis; Postoperative Co | 2014 |
Acute behavioural disturbance associated with phenibut purchased via an internet supplier.
Topics: Adult; Alcohol Drinking; Delirium; Dronabinol; Emergency Service, Hospital; Female; gamma-Aminobutyr | 2015 |
Enigmatic Fever and Delirium in a Critically Ill Patient.
Topics: Adult; Amines; Critical Illness; Cyclohexanecarboxylic Acids; Delirium; Fever; Gabapentin; gamma-Ami | 2015 |
A case of infant delirium in the neonatal intensive care unit.
Topics: Amines; Analgesics, Opioid; Anti-Anxiety Agents; Cardiac Catheterization; Cyclohexanecarboxylic Acid | 2017 |
Gabapentin-induced delirium and dependence.
Topics: Adult; Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Delirium; Gabapentin; gamma-Am | 2009 |
Reversible delirium in an advanced cancer patient.
Topics: Amines; Analgesics; Analgesics, Opioid; Bone Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, No | 2012 |
Delirium, psychosis, and visual hallucinations induced by pregabalin.
Topics: Adult; Analgesics; Delirium; Female; gamma-Aminobutyric Acid; Hallucinations; Humans; Low Back Pain; | 2012 |
[IMMEDIATE CLINICAL RESULTS WITH GAMMA AMINOBUTYRIC ACID B6 IN SCHIZOPHRENIAS AND DELIRIUMS].
Topics: Aminobutyrates; Biochemical Phenomena; Biochemistry; Delirium; gamma-Aminobutyric Acid; Mental Disor | 1963 |
Psychotogenic drugs and delirium pathogenesis: the central role of the thalamus.
Topics: Cerebral Cortex; Corpus Striatum; Delirium; Dopamine; gamma-Aminobutyric Acid; Humans; Models, Neuro | 2005 |
Delirium as a disorder of consciousness.
Topics: Acetylcholine; Aged; Arousal; Attention; Awareness; Brain Stem; Cerebral Cortex; Child; Consciousnes | 2007 |
Abstinence symptoms after withdrawal of tranquillising drugs: is there a common neurochemical mechanism?
Topics: Anti-Anxiety Agents; Delirium; GABA Antagonists; gamma-Aminobutyric Acid; Humans; Models, Biological | 1982 |